Show simple item record

dc.contributor.authorChan, Arlene
dc.date.accessioned2017-11-24T05:25:59Z
dc.date.available2017-11-24T05:25:59Z
dc.date.created2017-11-24T04:48:54Z
dc.date.issued2016
dc.identifier.citationChan, A. 2016. HER2 positive metastatic breast cancer: What happens after first line failure?. Cancer Forum. 40 (3).
dc.identifier.urihttp://hdl.handle.net/20.500.11937/58480
dc.description.abstract

For women with metastatic HER2 positive breast cancer, the introduction of trastuzumab into routine practice was transformative. More recently, the addition of pertuzumab has further improved the outlook. However in almost all cases, the disease unfortunately progresses. Much research has gone into what to do next. Fortunately we now have evidence to support a number of strategies, with the underlying understanding that HER2 blockade should be continued for as long as possible. Historically, lapatinib was the first anti-HER2 agent to show activity after relapse on trastuzumab. Subsequently the effectiveness of T-DM1 (Kadcyla) has been demonstrated, as has the use of alternating chemotherapy agents with trastuzumab. Research is now focussed on understanding and combating the mechanisms of resistance to anti-HER2 agents that inevitably develop. Promising data suggest that mTOR inhibitors, PI3 kinase inhibitors and immune-Activating therapies may be helpful.

dc.publisherCancer Council Australia
dc.titleHER2 positive metastatic breast cancer: What happens after first line failure?
dc.typeJournal Article
dcterms.source.volume40
dcterms.source.number3
dcterms.source.issn0311-306X
dcterms.source.titleCancer Forum
curtin.departmentCurtin Medical School
curtin.accessStatusFulltext not available


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record